Prota Therapeutics

About

Prota Therapeutics is a Melbourne-based biotech developing oral immunotherapies for food allergy remission, advancing lead candidate PRT120 into Phase 3, based on Murdoch Children's Research Institute-derived IP.

Mission

Prota Therapeutics is a Melbourne, Australia–based biotech focused on developing novel oral immunotherapy treatments intended to induce remission of food allergies. Its lead program is PRT120, an oral therapy for peanut allergy that is advancing into Phase 3 clinical investigation. The company intends to use newly raised funds to accelerate that Phase 3 trial. Prota was established in 2016 and is led by Executive Chairman Kelly Constable. Its technology is based on over 15 years of research led by Professor Mimi Tang at the Murdoch Children’s Research Institute, and Prota holds intellectual property covering the proprietary food immunotherapy technology developed at MCRI. The recent financing strengthens the company’s position to continue clinical development of its oral immunotherapy programs. Prota Therapeutics is an Australian life sciences firm. The article reports that OneVentures invested $7.4 million in Prota. No details on Prota’s products, pipeline, or operational metrics were provided in the article. The financing instrument, valuation, terms and intended use of proceeds were not disclosed. No other investors or past rounds were mentioned. The mention of the investment appeared in a broader Australia deals roundup that also noted a separate Bain-backed merger between Camp Australia and Junior Adventures.

Quick Facts